Ipamorelin Peptide + Tesamorelin Blend

Compound Class and Structure Tesamorelin & Ipamorelin blend is a co-formulated preparation of two synthetic peptides supplied as a lyophilised powder in a sealed glass vial. Tesamorelin is a stabilised analogue of human growth hormone–releasing hormone, built on the 44-amino-acid GRF(1-44) amide sequence and carrying a trans-3-hexenoyl group at the N-terminus, a modification associated in the literature with slower enzymatic cleavage by dipeptidyl peptidase-4. Ipamorelin is a short pentapeptide growth hormone secretagogue (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with C-terminal amidation and non-natural residues that confer resistance to exopeptidase trimming. The two molecules belong to separate structural and pharmacological families and are combined so that both receptor routes can be examined within a single experimental article. Receptor Pharmacology and Signalling Tesamorelin engages the GHRH receptor (GHRHR), a class B1 G protein-coupled receptor expressed on pituitary somatotrophs. Canonical coupling runs through Gs, adenylyl cyclase and cAMP accumulation, with downstream protein kinase A activity, CREB phosphorylation and Pit-1/POU1F1-associated transcriptional regulation of the GH1 locus. Ipamorelin is a selective agonist at the growth hormone secretagogue receptor (GHSR1a), a class A GPCR that signals principally through Gq/11, phospholipase C-beta, inositol trisphosphate generation and mobilisation of intracellular calcium; GHSR1a is also studied for constitutive activity